Objective: This study examined the relationship between postmortem precuneus cholinergic enzyme activity, Pittsburgh compound B (PiB) binding, and soluble amyloid-␤ concentration in mild cognitive impairment (MCI) and Alzheimer disease (AD).
(MCI), or mild AD (mAD). The precuneus exhibits high levels of PiB PET retention and may be selectively vulnerable to structural and functional alterations in preclinical and early AD. [5] [6] [7] [8] Neuroimaging studies implicate the precuneus in episodic memory retrieval and as a component of the brain's default mode network, 9, 10 which is disrupted in the presence of amyloid pathology. 11, 12 The parietal cortex receives cholinergic innervation from select subfields of the nucleus basalis, 13 which is important in cognitive function. Whether amyloid deposition marked by in vivo PiB PET retention in the precuneus affects cholinergic enzyme activity has important implications for timely therapeutic intervention during the earliest phase of AD. Subjects. Forty-two cases matching our inclusion criteria were randomly chosen from brain banks of the Rush Religious Orders Study, a longitudinal clinicopathologic study of aging and AD in retired Catholic clergy, 14 the University of Kentucky's community-dwelling cohort, 15 and the University of Pittsburgh Alzheimer Disease Research Center. 16 Sample size was limited by availability of frozen and fixed precuneus tissue. On the basis of the last antemortem clinical diagnosis, cases were assigned to 3 clinical groups (NCI, n ϭ 14; MCI, n ϭ 13; and AD, n ϭ 15) matched by age, gender, years of education, and postmortem interval. The AD case subjects had mild to moderate disease severity (Mini-Mental State Examination [MMSE] score 10 -27) . The diagnosis of AD was made using standard diagnostic criteria. 17 MCI was defined as impairment on neuropsychologic testing, but without diagnosis of dementia by the examining neurologist, 14 criteria similar to those used at other centers. 18, 19 Among the cases of MCI, 9 were amnestic MCI (aMCI). Consensus conferences of neurologists and neuropsychologists reviewed clinical data, medical records, and interviews with family members and assigned a final clinical diagnosis. Neuropathologic diagnosis was based on the National Institute on Aging (NIA)-Reagan criteria, 20 recommendations of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD), 21 and Braak staging of neurofibrillary tangles. 22 Patients with pathology other than AD (e.g., stroke or Parkinson disease) were excluded from the study. All cases were deidentified and randomly assigned a unique identifier throughout the study. Investigators were blinded to case demographics and diagnosis.
Tissue samples. Precuneus gray matter was harvested at autopsy and frozen (Ϫ80°C), homogenized on ice in phosphatebuffered saline (PBS; 150 mg/mL), and divided into 2 aliquots. One was prepared for ChAT enzyme activity assay, and the second was rehomogenized in tissue homogenization buffer (250 mM sucrose, 20 mM Tris base, and protease inhibitors [Sigma 8340 protease inhibitor cocktail; 10 L/mL buffer]) and divided into 2 aliquots; one was prepared for A␤ ELISA, and the second was diluted to 10 mg tissue/mL with potassium PBS (pH 7.4) for the [ 3 H]PiB binding assay.
Quantitative neuropathologic analyses. Formalin-fixed precuneus tissue was available from 32 of 42 cases examined. Samples were fixed in 10% buffered formalin for 48 hours, paraffin-embedded, cut into 8-m-thick sections, and stained with the Bielschowsky silver method. A neuropathologist blinded to clinical diagnosis and demographic data performed the analyses. Diffuse plaques (DPs) and neuritic plaques (NPs) 24 and mimics the low nanomolar concentrations of radioactive PiB achieved in human brain during a PET study.
A␤ ELISA. The A␤42 peptide concentration was quantified in diethylamine (DEA)-soluble A␤ fractions as described previ- ously. 23 The DEA-soluble fraction was prepared by centrifuging the precuneus homogenate aliquot described above at 135,000 ϫ g at 4°C for 1 hour and neutralizing the supernatant with 0.5 M Tris-Cl. The A␤ concentration was assayed using a fluorescentbased ELISA (Biosource, Camarillo, CA) with a capture antibody specific for the NH 2 terminus of human A␤ (amino acids 1-16) and detection antibodies specific for the neoepitope at the 42-amino acid end of A␤. Values were determined from standard curves using synthetic A␤42 peptide (Biosource) and are expressed as picomoles per gram wet brain tissue.
ChAT activity assay. ChAT activity was measured using a modification of the Fonnum method. 25 Aliquots were rehomogenized in buffer containing 10 mM disodium EDTA and 0.5% Triton X-100 in distilled water. All samples were run in triplicate. The reaction was initiated by the addition of 5 L of sample or blanks (homogenizing buffer) to Eppendorf tubes containing 10 L of assay mixture consisting of 250 L of incubation buffer (100 mM sodium phosphate buffer, 600 mM sodium chloride, 20 mM choline chloride, and 10 mM disodium EDTA), 250 L of [ 14 Although cases were matched on age, gender, years of education, and postmortem interval, the residual effects of these potential confounders were explored in multivariate analyses including partial correlation or multiple regression; the findings remained essentially unchanged and are presented as unadjusted (univariate) results. Nonparametric methods were used whenever possible because they are more robust to outliers and non-normality in the data. No subgroup analysis was conducted, and statistical analyses were based on all available data, with any missing value documented by a footnote in tables 1 and 2. The level of statistical significance was set at 0.05 (2-sided).
RESULTS Case demographics and clinical and neuropathologic characteristics. NCI, MCI, and mAD groups differed by MMSE scores, Braak scores, and CERAD and NIA-Reagan diagnoses of AD (all p Ͻ 0.001), but not by age, gender, years of education, APOE allele status, or postmortem delay (tables 1 and 2). Post hoc analyses revealed that the mAD group had lower MMSE scores and a more advanced Braak stage of NFT pathology than the MCI and NCI groups, whereas the latter 2 groups were not statistically different. NIA-Reagan scores were higher in the mAD group than in the NCI and MCI groups and higher in the MCI than in the NCI group. The mAD group had more advanced CERAD diagnoses than the NCI group, but differences between the mAD and MCI groups were not statistically significant ( significantly more NPs, whereas there were no significant increases in precuneus DPs and NFTs. Compared with the mAD group, the MCI group had fewer DPs, but the 2 groups were not statistically different when compared for NPs or NFTs. The mAD group had more DPs, NPs, and NFTs in the precuneus than the NCI group.
ChAT activity, [ 3 H]PiB binding, and soluble A␤42 in
clinical groups. Precuneus ChAT activity differed among the 3 clinical groups ( p ϭ 0.02). ChAT activity in the mAD group was 31% lower than that in the NCI group ( p ϭ 0.007) and 22% lower than that in the MCI group; however, the latter difference was not significant statistically. ChAT activity was not different between the NCI and MCI groups (table 3, figure 1 ). . The median level of PiB binding in the MCI group was 1.5-fold higher than that in the NCI group, but this difference was not statistically significant. The precuneus A␤42 concentration showed an 11.7-fold increase in the mAD group compared with that in the NCI group ( p Ͻ 0.0001) and a 2-fold increase in mAD compared with that in the MCI group ( p Ͻ 0.0008; figure 1 ). The median level of soluble A␤42 concentration in the MCI group was 5.7-fold higher than that in the NCI group, but this difference was not statistically significant (table 3) .
Associations of biochemical, clinical, and neuropatho-
logic measures. Across all cases, we observed a decrease in levels of ChAT activity in the precuneus in parallel with increases in [ 3 H]PiB binding (r ϭ Ϫ0.46, p ϭ 0.003; figure 2A ) and soluble A␤42 concentration (r ϭ Ϫ0.46, p ϭ 0.0013; figure 2B ). Increased [ 3 H]PiB binding in the precuneus correlated directly with the soluble A␤42 concentration (r ϭ 0.72, p Ͻ 0.0001; figure 2C higher [ 3 H]PiB binding (r ϭ 0.74 and 0.68, respectively, both p Ͻ 0.0001), and higher concentration of soluble A␤42 (r ϭ 0.63, p Ͻ 0.0001 and r ϭ 0.55, p ϭ 0.0005). Precuneus ChAT activity correlated inversely with numbers of regional NPs (r ϭ Ϫ0.56, p ϭ 0.0009), whereas associations with DPs and NFTs were weak (r ϭ Ϫ0.43, p ϭ 0.015 and r ϭ Ϫ0.36, p ϭ 0.044). Precuneus [ 3 H]PiB and A␤42 levels correlated directly with regional DPs and NPs (r ϭ 0.83 and r ϭ 0.67, both p Ͻ 0.0001) and NFTs (r ϭ 0.61, p Ͻ 0.0002). The presence of the APOE*4 allele was associated with lower ChAT activity and higher levels of [ 3 H]PiB binding and soluble A␤42 concentration (all p Ͻ 0.0001) in the precuneus.
DISCUSSION
The present study demonstrates stable ChAT activity despite accumulating amyloid load in the precuneus of MCI, expanding previous observations in other neocortical regions in prodromal AD. 26, 27 Interestingly, the superior frontal cortex (SFC), which also exhibits high levels of PiB PET retention and amyloid pathology early in AD, 3, 28 displays increased ChAT activity in MCI, suggesting that upregulated SFC cholinergic activity is a compensatory response during the transition to AD. 27 The precuneus appears to lack a similar plasticity. Furthermore, our finding of reduced precuneus ChAT activity in mild AD cases is in contrast with reports of stable cholinergic levels in other neocortical regions in early AD. 26, 27 The mechanisms underlying cortical region-specific differences in amyloid pathology and cholinergic plasticity changes during early clinical stages of disease remain unclear. Although numbers of precuneus NPs were higher in MCI than in NCI, biochemical measures of amyloid overlapped substantially, consistent with reports of amyloid-burdened individuals in both clinical groups. 8,29 -34 Herein, one NCI case subject exhibited normal global cognition (MMSE score ϭ 30) despite advanced amyloid pathology. Another NCI case subject with an unusually high DEA-soluble A␤42 concentration was the only APOE*4/4 homozygous subject in our study, supporting the fact that APOE*4 status affects soluble A␤42 levels. 35 However, its [ 3 H]PiB binding, a marker of insoluble amyloid load and in vivo PiB PET retention, 23 was average for the NCI group. A previous report of an APOE*3/4 AD case subject with low [ 3 H]PiB bind- ing and high A␤ concentrations suggested that this disparity was due to a unique profile of A␤ oligomers, truncated A␤ species, and high vascular A␤ pathology. 36 In our study, excessive vascular pathology was an exclusion criterion for case selection. The spectrum of truncated A␤ species in our PiBrefractory NCI case subject remains to be investigated. Despite these occasional mismatches, precuneus [ 3 H]PiB binding and soluble A␤42 concentration correlated strongly with each other and with MMSE scores. MMSE, a measure of global cognitive function, relies on integration of activity from multiple cortical associational areas including the precuneus as either a part of the cortical default mode network or a complex brain circuitry involved in attention and working memory. Because the present findings were generated from 3 clinical cohorts, they suggest general applicability of the data across subject populations. However, the relatively small number of cases in the present study preclude a definite conclusion regarding the relationship between amyloid measures and cognition.
The heterogeneity of the current MCI cohort, with 4 of 13 cases classified as nonamnestic MCI (naMCI), may have contributed to the lack of differences in ChAT activity and the low magnitude of differences in PiB binding and soluble A␤42 concentration between the NCI and MCI groups. Three of the 4 naMCI case subjects had the lowest detectable A␤42 concentrations, low PiB binding levels, and high ChAT activity values (figure 1), suggesting that these subjects with naMCI may not be at risk to convert to AD or would develop AD only much later in life. 8 When the MCI group was restricted to those with aMCI (n ϭ 9), [ 3 H]PiB binding did not differ from that in the AD group, and a trend toward increased soluble A␤42 levels in aMCI was seen compared with that for the NCI group. In contrast, ChAT activity levels in the aMCI group did not differ significantly from those in the NCI and AD groups, suggesting that during the clinical progression from NCI to aMCI to AD, soluble A␤42 increases before a decline in cholinergic enzyme activity and is, therefore, an important therapeutic target. However, similar to other cross-sectional neuropathologic studies, we cannot determine the time course or a causal relationship between these pathologic events in the precuneus. The associations between cholinergic and global cognitive deficits and buildup of A␤ pathology in the precuneus are reminiscent of the relationship between increased precuneus amyloid load on PiB PET scans and decreased regional metabolism measured by [ 18 F]fluoro-2deoxy-D-glucose PET (considered to be a surrogate marker of synaptic activity) in AD but not in MCI and amyloid-positive NCI case subjects. 37 It would be of value to examine changes in synaptic markers in relation to [ 3 H]PiB binding in the precuneus and other neocortical regions.
In a previous clinicopathologic study, the [ 11 C]PiB PET imaging signal and postmortem [ 3 H]PiB binding in the same subject correlated strongly and [ 3 H]PiB binding levels greater than 200 pmol/mg corresponded to PiB PET-positive values above a conservative positive cutoff determined as an atrophy-corrected distribution volume ratio of 1.4. 23, 38 In the present study, precuneus [ 3 H]PiB binding determined postmortem was greater than 200 pmol/mg in all AD case subjects (figure 1), suggesting that they would have been PiB PET-positive if imaged before death. Interestingly, 46% of MCI and 21% of NCI case subjects in the present study also had precuneus [ 3 H]PiB binding greater than 200 pmol/mg (figure 1), suggesting that they would probably have been PiB PET-positive as well. These observations are comparable to reports from imaging studies in live subjects. 8, 34, 37, 39 Our study demonstrates that precuneus ChAT activity decreases in parallel with increases in PiB binding and soluble A␤42 concentration. Thus, the positive PiB PET signal in the precuneus of amyloidburdened NCI and MCI case subjects probably reflects ongoing impairment of cholinergic neurotransmission, which becomes detectable only after the onset of clinical AD. This finding suggests a temporal window for the use of cholinomimetic therapies, alone or in combination with antiamyloid therapies, to slow the progression of AD. Such therapy may prove to be effective in individuals with preclinical cases in whom the cortical amyloid load has not reached a plateau. 
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